Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML
Ming Hong, Han Zhu, Qian Sun, Yu Zhu, Yi Miao, Hui Yang, Hai‐Rong Qiu, Jianyong Li, Sixuan Qian
Abstract
mutations. Multivariate analysis showed that patient age above 75 years, high-risk status, and genetic anomalies, like deletions in chromosomes 5 and/or 7, were significant variables in predicting OS. D-CAG regimen tends to improve the prognosis of a subgroup of elderly patients with high-risk AML.
Topics & Concepts
AclarubicinCytarabineDecitabineMedicineOncologyInternal medicineLeukemiaBiologyDNA methylationBiochemistryGene expressionGeneAcute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors ResearchAcute Lymphoblastic Leukemia research